Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor (CAR) T-cell therapies for the potential risk for secondary T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback